Alfa Digital Co., Ltd.
Update:2026/01/07
Industries
Main Industry
Software
Main Product/Service
Future PharmaTech uses its proprietary “Future‑AI platform,” integrating drug repurposing and mechanism simulation to develop novel compounds capable of penetrating the blood‑brain barrier (BBB), targeting conditions such as vascular dementia (VD) and ere
Founded Year
2023
Unified Business No.
94004036
Status
Active
Number of Employees
0
Total Paid-in
Capital
8,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Future PharmaTech, founded in 2021, focuses on neurological and vascular disorders, leveraging its proprietary AI‑driven drug discovery platform and nanomedicine technologies to rapidly develop effective, safe and precision therapies designed to improve p